Copaxone is selling like hotcakes. US Copaxone sales increased 29% year-over-year (11% quarter-to-quarter) to a record annualized run rate of $2.6B (#msg-59647292).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”